Back to Search
Start Over
Is a treat-to-target approach to lipid-lowering therapy appropriate in patients with chronic kidney disease? A prospective French cohort study
- Source :
- Journal of Nephrology, Journal of Nephrology, Italian Society of Nephrology/Springer, 2021, 34 (5), pp.1467-1477. ⟨10.1007/s40620-021-01086-y⟩, Journal of Nephrology, 2021, 34 (5), pp.1467-1477. ⟨10.1007/s40620-021-01086-y⟩
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- International audience; BACKGROUND: Whereas European guidelines recommend adjusting lipid-lowering therapy (LLT) to meet prespecified targets ('treat-to-target') for low-density lipoprotein cholesterol (LDL-C), other guidelines do not ('fire and forget'). In a large observational prospective cohort, we sought to evaluate which strategy could be associated with better cardiovascular outcomes in chronic kidney disease (CKD). METHODS: In CKD-REIN, patients (CKD stages 3 and 4) on LLT were categorized according to achievement of LDL-C targets for high and very high cardiovascular risk (\textless 2.6 and \textless 1.8 mmol/L, respectively) at baseline. Primary outcome was fatal/non-fatal atheromatous cardiovascular disease (CVD). Secondary outcomes were non-atheromatous CVD, atheromatous or non-atheromatous CVD, and major adverse cardiovascular events. RESULTS: The population comprised 1521 patients (68 ± 12 years, 31% women, mean estimated glomerular filtration rate [eGFR] 35 mL/min/1.73 m(2)). Overall, 523 (34%) met their LDL-C targets at baseline. Median follow-up was 2.9 years (interquartile range 2.2-3.0). Incidence rates per 100 patient-years were 6.2% (95% confidence interval [CI] 5.5-7.0) for atheromatous CVD, 9.2% (8.3-10.1) for non-atheromatous CVD, 15.2% (14.0-16.4) for atheromatous/non-atheromatous CVD, and 6.3% (5.5-7.1) for major adverse cardiovascular events. Corresponding rates in patients who achieved targets were 6.6%, 9.8%, 16.1%, and 6.3%, respectively. Target achievement was not associated with risk of fatal/non-fatal atheromatous CVD (adjusted hazard ratio 1.04, 95% CI 0.76-1.44, p = 0.77) or fatal/non-fatal atheromatous or non-atheromatous CVD (0.98, 0.78-1.23, p = 0.91). CONCLUSIONS: These findings do not appear to support a treat-to-target approach in CKD patients on LLT, and may favor the hypothesis of an advantage of fire-and-forget. Randomized trials are needed to confirm this theory.
- Subjects :
- Nephrology
Male
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
Population
030232 urology & nephrology
Renal function
Hyperlipidemias
030204 cardiovascular system & hematology
03 medical and health sciences
0302 clinical medicine
Interquartile range
Risk Factors
Internal medicine
Chronic kidney disease
medicine
Humans
Low-density lipoprotein cholesterol
Prospective Studies
Renal Insufficiency, Chronic
Prospective cohort study
education
Aged
Hypolipidemic Agents
Aged, 80 and over
education.field_of_study
Lipid-lowering drugs
business.industry
Hazard ratio
Cholesterol, LDL
Middle Aged
medicine.disease
Cardiovascular disease
Lipids
3. Good health
[SDV] Life Sciences [q-bio]
Cardiovascular Diseases
Female
business
Cohort study
Kidney disease
Subjects
Details
- Language :
- English
- ISSN :
- 11218428 and 17246059
- Database :
- OpenAIRE
- Journal :
- Journal of Nephrology, Journal of Nephrology, Italian Society of Nephrology/Springer, 2021, 34 (5), pp.1467-1477. ⟨10.1007/s40620-021-01086-y⟩, Journal of Nephrology, 2021, 34 (5), pp.1467-1477. ⟨10.1007/s40620-021-01086-y⟩
- Accession number :
- edsair.doi.dedup.....b22a6e3366caa8199bebf6f9e1b08c01